Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patrick Griffith

Interventional Pain Medicine North Kansas City, MO Medical Doctor

NPI 1366524076 CMS profile 288456

2800 Clay Edwards Dr, North Kansas City, MO 64116

Open in the dashboard

General payments

$3,239

247 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Patrick Griffith of North Kansas City, MO is reported in the CMS Open Payments database as having received $3,239 across 247 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 44th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $23 1
2024 General $738 60
2023 General $1,067 56
2022 General $486 28
2021 General $462 26
2020 General $336 74
2019 General $127 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Griffith
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Patrick Griffith were reported at $23. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Patrick Griffith Interventional Pain Medicine median Middle half National median
2019 $127 $684 $216–$2,079 $163
2020 $336 $382 $122–$1,109 $114
2021 $462 $552 $167–$1,554 $132
2022 $486 $605 $187–$1,924 $149
2023 $1,067 $671 $195–$1,915 $160
2024 $738 $684 $206–$1,837 $164
2025 $23 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,096 145 payments
  2. Boston Scientific Corporation $571 9 payments
  3. Nevro Corp. $540 10 payments
  4. Medtronic USA, Inc. $336 74 payments
  5. Relievant Medsystems, Inc. $293 3 payments
  6. SPR Therapeutics, Inc $212 3 payments
  7. Abiomed $168 1 payment
  8. Vertos Medical, Inc. $14 1 payment
  9. Saluda Medical Americas, Inc. $10 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,970 243 payments
  2. Travel and Lodging $264 3 payments
  3. Education $5 1 payment
Products named General payments · program years 2019–2025
  1. Intracept Pain $802 10 payments
  2. INTELLIS ADAPTIVESTIM $661 76 payments
  3. Omnia $261 2 payments
  4. SPRINT PNS System $212 3 payments
  5. VECTRIS Spinal Cord Neurostimulation $175 71 payments
  6. Intracept Pain $173 2 payments
  7. Intracept Pain $173 2 payments
  8. Intracept Pain $173 2 payments
  9. Impella $168 1 payment
  10. VECTRIS Spinal Cord Neurostimulation $167 13 payments
  11. Other $874 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,979

Median for Interventional Pain Management: 1,220

Drug cost

$38,745

Median for Interventional Pain Management: $39,344

Branded share of claims

38.3%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 506 $11,079
Pregabalin Generic 238 $5,815
Gabapentin Generic 279 $5,409
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 169 $5,082
Oxycodone Hcl Generic 176 $3,932
Morphine Sulfate Er Morphine Sulfate Brand 71 $1,572
Tramadol Hcl Generic 159 $1,379
Baclofen Generic 45 $920
Duloxetine Hcl Generic 39 $862
Methadone Hcl Generic 29 $589

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$182,940

Medicare's payments for the services billed

Medicare patients

470

Average age 74

Services billed

2,052

284 women, 186 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 32%
Diabetes 30%
Depression 30%
Chronic kidney disease 26%
COPD 20%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

247 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record